Industries > Pharma > Non-Small Cell Lung Cancer (NSCLC) Drugs Market Forecast 2017-2027

Non-Small Cell Lung Cancer (NSCLC) Drugs Market Forecast 2017-2027

Chemotherapy, EGFR and ALK Inhibitors, VEGF/VEGFR Inhibitors, Immunotherapy, Other

PUBLISHED: 29 June 2017
PAGES: 172
PRODUCT CODE: PHA0207
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
SKU: PHA0207 Categories: ,

The Non-Small Cell Lung Cancer (NSCLC) Drugs market is estimated at $7.86bn in 2016 and is expected to grow at a CAGR of 4.9% in the first half of the forecast period. The market is expected to grow at a CAGR of 3.2% during the full forecast period. In 2016, the chemotherapy segment generated a revenue of $3.28bn and represented 41.7% of the total NSCLC drugs market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 172-page report you will receive 133 charts – all unavailable elsewhere.

The 172-page report provides clear detailed insight into the Non-Small Cell Lung Cancer (NSCLC) Drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

Non-Small Cell Lung Cancer (NSCLC) Drugs market forecasts from 2017-2027

• This report also breaks down the revenue forecast for the main therapeutic segments:
• Chemotherapy
• EGFR and ALK Inhibitors
• VEGF / VEGFR Inhibitors
• Immunotherapy

Non-Small Cell Lung Cancer (NSCLC) Drugs Market Forecast 2017-2027

• This report provides revenue forecast to 2027 for the leading drugs in this market:
Alimta (pemetrexed) by Eli Lilly
Avastin (bevacizumab) by Roche
Tarceva (erlotinib) by Roche
Iressa (gefitinib) by AstraZeneca
Gilotrif (afatinib) by Boehringer Ingelheim
Xalkori (crizotinib) by Pfizer
Abraxane (paclitaxel Protein-Bound) by Celgene
Taxotere (docetaxel) by Sanofi
Cyramza (ramucirumab) by Eli Lilly
Zykadia (ceritinib) by Novartis
Opdivo (nivolumab) by Bristol-Myers Squibb

• This report provides individual revenue forecasts to 2027 for these regional and national markets:
• The US
• Japan
• Germany
• France
• Italy
• Spain
• The UK
• China
• Brazil
• Russia
• India
• Rest of the World

• This report also includes a chapter on R&D which discusses some of the most promising and prominent late-stage candidates

• Our study includes a SWOT analysis of this industry and market

• Our study explores the issues and forces that influence the NSCLC drugs market:
• Genetic mutations allowing for targeted therapies, newer medicines offering improved treatment outcomes
• Treatment protocols by stage and for patient populations – maintenance, second-line and third-line therapies
• Regulators’ views and cost-effectiveness – challenges and opportunities in drug approvals, pricing, reimbursement and healthcare budgets
• Recent approval for the NSCLC indication – expanding treatment options
• Overcoming patent expiries and competition from generic drugs
• Identification of biomarkers for targeted therapies, advancing treatment protocols.

Visiongain’s study is intended for anyone requiring commercial analyses for the Non-Small Cell Lung Cancer (NSCLC) Drugs market. You find data, trends and predictions.

Buy our report today Non-Small Cell Lung Cancer (NSCLC) Drugs Market Forecast 2017-2027: Chemotherapy, EGFR and ALK Inhibitors, VEGF/VEGFR Inhibitors, Immunotherapy, Other.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Non-Small Cell Lung Cancer (NSCLC) Drugs Market Forecast 2017-2027


Download sample pages

Complete the form below to download your free sample pages for Non-Small Cell Lung Cancer (NSCLC) Drugs Market Forecast 2017-2027


Latest Pharma news

Visiongain Publishes Pharmaceutical Spray Drying Market Report 2021-2031

The rising prevalence of oncological disorders, lung infections, rising demand for customised drugs coupled with new orphan diseases discoveries, are few of the major reasons responsible for development of pharmaceutical spray drying market.

25 October 2021

READ

Visiongain Publishes Clinical Trial Supplies Market Report 2021-2031

Deviating from protocols raises the danger of missing or delaying data collection from current investigations. This highlights the growing importance of digital medicine, which is being aided by advancements in cloud, mobile, and IoT technology.

11 October 2021

READ

Visiongain Publishes Drug Discovery Informatics Market Report 2021-2031

High performance HPC and supercomputing technology have evolved substantially in China in the last decades, leading to extraordinary accomplishments. HPC-based and combined pharmaceutical chemical and computational biology computational discovery and design has become a significant technique in drug research and development and is sponsored financially by the Chinese government.

07 October 2021

READ

Visiongain Publishes Pharma Wholesale and Distribution Market Report 2021-2031

Many health-care organizations are seeing organic growth at levels that their supply networks were never designed to handle. Others are frantically attempting to integrate diverse technology and procedures as part of a consolidation effort.

06 October 2021

READ

Categories